Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 15 | 2025 | 297 | 3.150 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2025 | 220 | 1.920 |
Why?
|
| Acute Coronary Syndrome | 7 | 2025 | 241 | 1.820 |
Why?
|
| Aortic Valve Stenosis | 5 | 2025 | 360 | 1.820 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 121 | 1.670 |
Why?
|
| Coronary Stenosis | 2 | 2024 | 82 | 1.540 |
Why?
|
| Coronary Angiography | 7 | 2024 | 485 | 1.230 |
Why?
|
| Coronary Artery Bypass | 10 | 2023 | 539 | 1.040 |
Why?
|
| Aortic Valve | 5 | 2025 | 469 | 0.970 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 638 | 0.890 |
Why?
|
| Coronary Artery Disease | 9 | 2025 | 894 | 0.890 |
Why?
|
| Nitroglycerin | 1 | 2024 | 23 | 0.890 |
Why?
|
| Coronary Vasospasm | 1 | 2024 | 13 | 0.880 |
Why?
|
| Lithotripsy | 2 | 2021 | 27 | 0.860 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 19 | 0.840 |
Why?
|
| Myocardial Infarction | 6 | 2024 | 1102 | 0.810 |
Why?
|
| Vasodilator Agents | 1 | 2024 | 214 | 0.790 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 22 | 0.780 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 213 | 0.750 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 462 | 0.570 |
Why?
|
| Treatment Outcome | 23 | 2025 | 13077 | 0.570 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 2090 | 0.530 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 181 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.520 |
Why?
|
| Stroke | 3 | 2022 | 1077 | 0.520 |
Why?
|
| American Heart Association | 1 | 2018 | 329 | 0.490 |
Why?
|
| Heart Diseases | 1 | 2020 | 526 | 0.480 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2022 | 459 | 0.470 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 807 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 396 | 0.460 |
Why?
|
| Atherosclerosis | 4 | 2023 | 1002 | 0.450 |
Why?
|
| Electrocardiography | 4 | 2024 | 1005 | 0.440 |
Why?
|
| Humans | 52 | 2025 | 134149 | 0.440 |
Why?
|
| Stents | 3 | 2025 | 877 | 0.400 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 778 | 0.390 |
Why?
|
| Angina Pectoris | 2 | 2024 | 67 | 0.380 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2024 | 285 | 0.380 |
Why?
|
| Postoperative Complications | 5 | 2019 | 3177 | 0.330 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2022 | 182 | 0.320 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 757 | 0.310 |
Why?
|
| Aged | 15 | 2025 | 21779 | 0.300 |
Why?
|
| Middle Aged | 14 | 2025 | 29427 | 0.260 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 1978 | 0.240 |
Why?
|
| Ultrasonography, Interventional | 2 | 2025 | 207 | 0.240 |
Why?
|
| Risk Factors | 11 | 2025 | 11179 | 0.230 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 40 | 0.210 |
Why?
|
| Comorbidity | 4 | 2022 | 1625 | 0.210 |
Why?
|
| Hospital Mortality | 4 | 2022 | 1096 | 0.200 |
Why?
|
| Vascular Calcification | 2 | 2020 | 67 | 0.200 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 211 | 0.190 |
Why?
|
| Cocaine-Related Disorders | 1 | 2024 | 204 | 0.190 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 130 | 0.180 |
Why?
|
| Endocarditis | 1 | 2022 | 106 | 0.180 |
Why?
|
| Hypothermia | 1 | 2021 | 64 | 0.180 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 47 | 0.170 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2021 | 21 | 0.170 |
Why?
|
| Inpatients | 2 | 2022 | 547 | 0.170 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 132 | 0.170 |
Why?
|
| Atherectomy, Coronary | 1 | 2020 | 10 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 170 | 0.170 |
Why?
|
| Male | 16 | 2025 | 66108 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2025 | 3742 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 158 | 0.170 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 97 | 0.170 |
Why?
|
| Carotid Arteries | 1 | 2021 | 151 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2012 | 376 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2021 | 187 | 0.160 |
Why?
|
| Heart Atria | 1 | 2022 | 337 | 0.160 |
Why?
|
| Aspirin | 1 | 2021 | 231 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 188 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3113 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 437 | 0.150 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 318 | 0.150 |
Why?
|
| Smoking | 1 | 2024 | 1136 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2301 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 331 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1217 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 382 | 0.130 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 70 | 0.130 |
Why?
|
| Cocaine | 1 | 2018 | 208 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 252 | 0.130 |
Why?
|
| Age Factors | 2 | 2020 | 2997 | 0.130 |
Why?
|
| Female | 15 | 2025 | 71905 | 0.130 |
Why?
|
| Pandemics | 2 | 2021 | 1190 | 0.120 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 17 | 0.120 |
Why?
|
| United States | 7 | 2023 | 11760 | 0.120 |
Why?
|
| Mitral Valve | 3 | 2022 | 272 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 696 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2015 | 268 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 253 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1306 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1416 | 0.100 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 108 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 169 | 0.100 |
Why?
|
| Colchicine | 1 | 2012 | 39 | 0.100 |
Why?
|
| Pericarditis | 1 | 2012 | 43 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1785 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 392 | 0.090 |
Why?
|
| Cause of Death | 1 | 2013 | 507 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 226 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 275 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2024 | 513 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2437 | 0.080 |
Why?
|
| Pneumonia | 1 | 2012 | 343 | 0.080 |
Why?
|
| Time Factors | 3 | 2025 | 6617 | 0.070 |
Why?
|
| Prognosis | 1 | 2018 | 5085 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 519 | 0.070 |
Why?
|
| Registries | 1 | 2015 | 1577 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2021 | 429 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2012 | 5213 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 756 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1906 | 0.050 |
Why?
|
| Radial Artery | 1 | 2022 | 30 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2013 | 17539 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 51 | 0.050 |
Why?
|
| Incidence | 2 | 2025 | 3416 | 0.050 |
Why?
|
| Mediastinum | 1 | 2022 | 47 | 0.050 |
Why?
|
| Hematoma | 1 | 2022 | 94 | 0.050 |
Why?
|
| Coma | 1 | 2021 | 57 | 0.050 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 25 | 0.040 |
Why?
|
| Adult | 4 | 2023 | 31976 | 0.040 |
Why?
|
| Survival Rate | 2 | 2019 | 2218 | 0.040 |
Why?
|
| Atherectomy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2021 | 107 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 262 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 107 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 127 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 250 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 5478 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 208 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 358 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 574 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 727 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 256 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 12 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 43 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 32 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.040 |
Why?
|
| Propranolol | 1 | 2018 | 130 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1195 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1200 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1488 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 667 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 856 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 519 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 649 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 680 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1391 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 622 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3666 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3754 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 6604 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 993 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 343 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 7214 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 1159 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1387 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 1338 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1909 | 0.020 |
Why?
|
| Texas | 1 | 2012 | 3715 | 0.010 |
Why?
|